Evoke Pharma (EVOK) Misses Q3 EPS by 14c

Evoke Pharma (NASDAQ: EVOK) reported Q3 EPS of ($0.34), $0.14 worse than the analyst estimate of ($0.20).

As of September 30, 2017, our cash and cash equivalents were approximately $10.4 million.

For earnings history and earnings-related data on Evoke Pharma (EVOK) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen